1.
Artificial Intelligence-Guided Endpoint Selection for Neuroprotection Trials in Glaucoma.
R da Costa Douglas, Scherer Rafael, Swaminathan Swarup S, Tseng Henry, A Medeiros Felipe
Am J OphthalmolApr 20260 citationsCohort Study
AI identified five most vulnerable visual field locations for glaucoma progression. These High-5 points showed significantly faster decline and better progressor discrimination, offering a sensitive functional endpoint for trials and personalized monitoring.